The authors reply

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1274-1275

  Bonaca, Marc P ^a   Braunwald, Eugene ^a   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE;

ASIAN; BLEEDING; CANCER RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LONG TERM CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ANALOGS AND DERIVATIVES; FEMALE; MALE; MYOCARDIAL INFARCTION;

ADENOSINE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84942113997     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508692     Document Type: Letter

References (5)

1. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-44.
2. Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and metaanalysis. Lancet 2015;385:792-8.
3. Unger EF. Weighing benefits and risks - the FDA's review of prasugrel. N Engl J Med 2009;361:942-5.
4. Roe MT, Ohman EM. Prasugrel versus clopidogrel for acute coronary syndromes. N Engl J Med 2013;368:188-9.
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.